Search
Jefferies London: BeOne Medicines announced a phase 3 success for its HER2 bispecific today in gastric cancer. John Oyler walks us through that and the whole pipeline
He hit on earnings, the HER2, degraders, and what BeOne is looking for in potential partners. Coverage brought to you by
Nov 17, 2025
ASH 2024: BeiGene CEO John Oyler on degraders, long-term BTK data, BCL2 inhibition, and being a global company
He describes the different profile of degraders vs small molecules, and highlights BeiGene's programs in BTK, EGFR, IRAK4, and others....
Dec 8, 2024
BeiGene CEO John Oyler discusses the breadth of the company's pipeline at #ASCO24
John Oyler discusses the company's marketed BTK and PD-1 therapies, and highlights a handful of programs and targets in the pipeline like...
Jun 2, 2024
John Oyler shares an update on BeiGene during San Francisco Healthcare Week
John Oyler discusses BeiGene's BTK, PD1, and other programs, and talks about the company's cost structure.
Jan 10, 2024
BeiGene on BTK Inhibitors and the Inflation Reduction Act.
John Oyler discusses BeiGene's BTK inhibitor Brukinsa and cautions about the Inflation Reduction Act.
Jan 10, 2023
.png){kind=logo}
